Sonoma Pharmaceuticals financials
$1.25−1.19%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Mar 31 | FY25 Mar 31 | FY24 Mar 31 | FY23 Mar 31 | FY22 Mar 31 | FY21 Mar 31 | FY20 Mar 31 | FY19 Mar 31 | FY18 Mar 31 | FY17 Mar 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.5M | $14.3M | $12.7M | $13.3M | $12.6M | $18.6M | $17.9M | $19.0M | $16.7M | $12.8M |
| Gross profit | $7.4M | $5.5M | $4.7M | $4.5M | $4.0M | $6.6M | $8.1M | $8.9M | $7.3M | $5.7M |
| Gross margin | 38.0% | 38.2% | 37.3% | 33.7% | 31.6% | 35.2% | 45.3% | 46.8% | 43.9% | 44.2% |
| Operating income | -$3.4M | -$2.9M | -$4.7M | -$5.2M | -$6.3M | -$4.0M | -$7.4M | -$11.5M | -$14.5M | -$13.0M |
| Net income | -$3.2M | -$3.5M | -$4.8M | -$5.2M | -$5.1M | -$4.0M | -$3.3M | -$11.8M | -$14.3M | $9.3M |
| Net margin | −16.3% | −24.2% | −38.0% | −38.8% | −40.3% | −21.2% | −18.5% | −62.2% | −86.0% | 72.3% |
| Diluted EPS | $-1.89 | $-2.79 | $-10.63 | $-30.40 | $-38.40 | $-39.40 | $-44.80 | $-255.40 | $-569.80 | $396.00 |
| EBITDA | -$3.3M | -$2.8M | -$4.5M | -$5.1M | -$6.1M | -$3.8M | -$7.1M | -$11.0M | -$14.0M | -$12.7M |
| Operating cash flow | -$3.9M | -$88.0K | -$2.4M | -$6.2M | -$4.2M | -$3.4M | -$4.6M | -$11.7M | -$12.4M | -$8.2M |
| Free cash flow | -$4.1M | -$168.0K | -$2.4M | -$6.4M | -$4.4M | -$3.6M | -$4.8M | -$11.8M | -$12.6M | -$8.6M |
| Diluted shares | 1.7M | 1.2M | 0.5M | 0.2M | 0.1M | 0.1M | 0.1M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.4M | $5.4M | $3.1M | $3.8M | $7.4M | $4.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $222.0K | $220.0K | $323.0K | $431.0K | $808.0K | $1.9M |
| Total assets | $14.0M | $13.7M | $14.7M | $16.2M | $18.8M | $15.0M |
| Total liabilities | $10.9M | $9.3M | $8.6M | $8.3M | $10.1M | $9.6M |
| Shareholders' equity | $3.1M | $4.4M | $6.1M | $8.0M | $8.7M | $5.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology